Another stellar and insightful contribution to the forum. Four words, well done. Perhaps you can do some maths for us.
In the Q ending Dec 2023, Starpharma reported pitiful revenue of $169,000 for the full 3 months which came from Viraleze and VivaGel.
Starpharma and @Starlink are now crowing over the fact that the Viraleze portion of this revenue (perhaps half maybe less) has gone up by 30%!
What an achievement. Looooool. It just goes to show that Viraleze revenue makes up an almost irrelevant portion of Starpharma’s income, despite all the registrations. Did anyone say KPI clawback?
Add to My Watchlist
What is My Watchlist?
